Symrise shifts pet nutrition focus to volume as prices normalize

Symrise is signaling that the next phase of growth in pet nutrition won’t come from higher prices. In its H1 2026 results, published July 30, the ingredient supplier said group growth accelerated in the second quarter, but its pet food division still posted a slight organic sales decline because nutrition prices continued to normalize. The company’s broader message was that the pricing reset is ongoing, while underlying demand is holding up better than the headline suggests. (symrise.com)

That theme has been building for months. In its Q1 2026 results, Symrise said pet nutrition saw a slight organic decline despite positive volumes, again because prices were normalizing. On the April 29 earnings call, management described the market as being at “market price,” with what CEO Jean-Yves Parisot characterized as more tactical normalization still playing out through negotiations on price and volume. GlobalPETS’ earlier coverage of the Q1 update similarly framed the slowdown as temporary rather than structural. (symrise.com)

The H1 numbers give that story more shape. Symrise reported first-half sales of €2.539 billion, with 2.0% organic growth, and said growth accelerated to 4.5% in Q2. In Taste, Nutrition & Health, H1 organic growth reached 3.2%, with reported sales of €1.53 billion and an adjusted EBITDA margin of 24.5%. In Q2 alone, that segment grew 4.9% organically, helped by food and beverage, while the pet food division recorded a slight decline tied specifically to continued nutrition price normalization. Symrise still reaffirmed its full-year 2026 outlook for 2% to 4% organic sales growth, a 21.5% to 22.5% adjusted EBITDA margin, and adjusted business free cash flow margin above 14%. (symrise.com)

There’s also a longer strategic backdrop here. Symrise has been leaning into pet nutrition innovation even while near-term pricing resets weigh on reported growth. In April, the company announced an investment in Bond Pet Foods, saying the partnership would help address supply-chain continuity and demand for more sustainable pet food ingredients, including proteins produced through precision fermentation. That suggests the company is treating the current pricing pressure as a cyclical issue, not a reason to pull back from the category. (symrise.com)

Outside commentary has broadly reinforced that read. Reuters’ coverage of the Q1 results noted that Symrise’s taste, nutrition, and health business, which includes pet food ingredients, outperformed expectations even as pricing remained a drag in some areas. Third-party earnings summaries also highlighted the same split: positive volumes in pet nutrition, but weaker reported sales because price normalization is still working through the business. Those sources should be read cautiously compared with the company’s own filings, but they point in the same direction as Symrise’s disclosures. (marketscreener.com)

Why it matters: For veterinary professionals, especially those following clinical nutrition, therapeutic diets, and the commercial health of pet food manufacturers, this is less about one company’s quarterly results and more about where the category may be headed. If ingredient pricing is stabilizing, manufacturers may get a clearer runway for planning formulations, promotions, and new product launches. At the same time, volume-led growth can indicate that demand is proving more resilient than revenue figures alone suggest, which matters when evaluating whether premium or function-forward nutrition lines still have room to expand. That doesn’t automatically translate into lower shelf prices for pet parents, but it can ease some pressure in the upstream supply chain. This is an inference based on Symrise’s pricing and volume commentary, not a direct company forecast for retail pet food prices. (symrise.com)

It’s also notable that Symrise is pairing this message with operational discipline. The company said efficiency gains from its ONE SYM transformation are being reinvested into growth opportunities, while freight and logistics costs remain affected by geopolitical tensions in the Middle East. In other words, pricing normalization in pet nutrition is happening at the same time other cost variables remain volatile, which could limit how quickly margin relief flows through the value chain. (symrise.com)

What to watch: The next key test is whether Symrise’s pet food business can turn positive on an organic basis in the second half of 2026 as price comparisons ease. Watch for management commentary on contract renewals, volume mix, and whether innovation bets such as sustainable proteins begin to show up as commercial growth drivers rather than just strategic positioning. Symrise’s reaffirmed 2026 guidance suggests it expects that improvement to build over the rest of the year. (symrise.com)